

RNS Number : 8024E
EKF Diagnostics Holdings PLC
15 April 2014

EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")

Investor Teach-In

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces it will be hosting an investor teach-in where Julian Baines, CEO, Paul Foulger, FD, and Andy Webb, CEO of the Molecular Diagnostics business will provide an overview of the EKF business on Monday 28 April 2014. No new material trading or financial information will be disclosed.

The event is open to all and will be held from 16:30 until 19:30 in the Black Bar at Rocket, 6 Adams Court, Old Broad Street, London, EC2N 1DX and will be followed by drinks and canapés.

For more information or to register to attend, contact Walbrook PR (contact details below).

General Meeting

The Board of EKF was pleased to announce, that at the General Meeting held on Friday 11th April 2014, the resolutions which were set out in the Notice of General Meeting included in the circular to shareholders in relations to the Acquisitions, Conditional Placing and Offer, dated 20 March 2014, were duly passed. Completions of the Acquisitions are therefore expected to occur on 17 April 2014.

Enquiries:

EKF Diagnostics Holdings plc
David Evans, Executive Chairman
Julian Baines, CEO
Paul Foulger, CFO

Tel: 029 2071 0570
Mob: 07740 084 452
Mob: 07788 420 859
Mob: 07710 989 255

Canaccord Genuity Limited

Tel: 020 7523 8350

Nominated Adviser/Corporate Broking
Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor /Chris Connors

Walbrook PR Limited
Paul McManus

Tel: 020 7933 8780
Mob: 07980 541 893 or
paul.mcmanus@walbrookpr.com

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market for a total consideration of \$4.0m (c.£2.4m). In March 2014, EKF also announced the intention to acquire Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers. Completions of the acquisitions of Selah Genomics Inc. and DiaSpect Medical AB. are expected to occur on 17 April 2014.

This information is provided by RNS
The company news service from the London Stock Exchange

END